Atara Biotherapeutics (ATRA) Equity Average (2014 - 2026)

Atara Biotherapeutics has reported Equity Average for 13 years, with the latest figure at -$37.9 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 50.24% year-over-year to -$37.9 million; the trailing twelve-month figure through Mar 2026 stood at -$37.9 million (up 50.24% YoY), and the FY2025 full-year result was -$67.9 million, down 7070.48% from the prior year.
• Equity Average for Q1 2026 stood at -$37.9 million, down from -$37.6 million in the prior quarter.
• The five-year high for Equity Average was $252.0 million in Q1 2022, with the low at -$104.6 million in Q2 2024.
• Historically, Equity Average has averaged $28.0 million across 5 years, with a median of -$21.7 million in 2023.
• The largest YoY upside for Equity Average was 64.41% in 2025 against a maximum downside of 16606.5% in 2025.
• Atara Biotherapeutics' Equity Average stood at $156.9 million in 2022, then sank by 84.58% to $24.2 million in 2023, then plunged by 488.12% to -$93.9 million in 2024, then soared by 60.0% to -$37.6 million in 2025, then slipped by 0.9% to -$37.9 million in 2026.
• The last three Equity Average figures came in at -$37.9 million (Q1 2026), -$37.6 million (Q4 2025), and -$35.8 million (Q3 2025), per Business Quant data.